mRNA Vaccines and RNAi Therapeutics Market By Disease Type, By Route of administration, By End user : Global Opportunity Analysis and Industry Forecast, 2021-2031

Description

List of Tables

The single protein-coding gene known as messenger ribonucleic acid (mRNA) is located in the genome and provides the basis for how cells make proteins. Mammalian cells are used in the laboratory to create mRNA vaccines and treatments, which have positive immunological properties. Some of the most common types of vaccines and therapies include non-replicating, in vivo self-replicating, self-amplifying, and in-vitro dendritic cell non-replicating mRNA. They are administered intravenously to trigger the immune system's virus-detection mechanisms and trigger the production of viral antigen proteins by the cells. The body's immunity is strengthened through enhancing B- and T-cell responses.

The major factors that drive the growth of the global mRNA vaccines and RNAi therapeutics market include increase in awareness about vaccination, increase in prevalence of cancer and cardiovascular disease and initiatives taken by government for large scale sequencing projects. In addition, target specialty and selectivity of treatment further propel the market growth. However, high cost of research, threat of failure and challenges in quantification of mRNA are expected to restrain the growth of the mRNA vaccines and RNAi therapeutics market during the forecast period. Conversely, application of mRNA technology and development of mRNA biomarker are anticipated to provide lucrative opportunities to the market players.

The mRNA vaccines and RNAi therapeutics market is segmented into disease type, route of administration, end user and region. According to disease type, the market is categorized into hereditary transthyretin-mediated amyloidosis genetic, acute hepatic porphyria, primary hyperoxaluria type 1 and atherosclerotic cardiovascular disease. On the basis of route of administration, it is segmented into IV infusion and subcutaneous. By end user, it is segregated into research institute and hospitals and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include: the Alnylam Pharmaceuticals, BioNTech AG, CureVac AG, eTheRNA Immunotherapy, Ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamon therapeutic Inc., Sanofi AG, SCM Lifescience Co., Ltd, Sarepta Therapeutics, Arcturus Therapeutics, Ionis pharmaceuticals Inc., Nutcracker Therapeutics, and TIBA Biotech.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mRNA vaccines and RNAi therapeutics market analysis from 2021 to 2031 to identify the prevailing mrna vaccines and rnai therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the mRNA vaccines and RNAi therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global mRNA vaccines and RNAi therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

Hereditary transthyretin-mediated amyloidosis genetic
Acute hepatic porphyria
Primary hyperoxaluria type 1
Atherosclerotic cardiovascular disease

By Route of administration

IV infusion
Subcutaneous

By End user

Research Institutes
Hospitals and clinics

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Alnylam Pharmaceuticals
- BioNTech AG
- Curevac AG
- Etherna Immunotherapies
- Ethris GMBH
- IN-CELL-ART
- Moderna Therapeutics
- Sangamo Therapeutics, Inc.
- Sanofi AG
- SCM Life Sciences (Argos Therapeutics, Inc. )
- Sarepta Therapeutics
- Arcturus Therapeutics
- Ionis Pharmaceuticals, Inc
- Nutcracker
- Tiba Biotech

Product Code: A17205

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Hereditary transthyretin-mediated amyloidosis genetic
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
4.3 Acute hepatic porphyria
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
4.4 Primary hyperoxaluria type 1
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
4.5 Atherosclerotic cardiovascular disease
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country

CHAPTER 5: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

5.1 Overview
- 5.1.1 Market size and forecast
5.2 IV infusion
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
5.3 Subcutaneous
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country

CHAPTER 6: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Research Institutes
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
6.3 Hospitals and clinics
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country

CHAPTER 7: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Disease Type
- 7.2.3 North America Market size and forecast, by Route of administration
- 7.2.4 North America Market size and forecast, by End user
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Market size and forecast, by Disease Type
  - 7.2.5.1.2 Market size and forecast, by Route of administration
  - 7.2.5.1.3 Market size and forecast, by End user
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Market size and forecast, by Disease Type
  - 7.2.5.2.2 Market size and forecast, by Route of administration
  - 7.2.5.2.3 Market size and forecast, by End user
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Market size and forecast, by Disease Type
  - 7.2.5.3.2 Market size and forecast, by Route of administration
  - 7.2.5.3.3 Market size and forecast, by End user
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Disease Type
- 7.3.3 Europe Market size and forecast, by Route of administration
- 7.3.4 Europe Market size and forecast, by End user
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Market size and forecast, by Disease Type
  - 7.3.5.1.2 Market size and forecast, by Route of administration
  - 7.3.5.1.3 Market size and forecast, by End user
  - 7.3.5.2 France
  - 7.3.5.2.1 Market size and forecast, by Disease Type
  - 7.3.5.2.2 Market size and forecast, by Route of administration
  - 7.3.5.2.3 Market size and forecast, by End user
  - 7.3.5.3 U.K.
  - 7.3.5.3.1 Market size and forecast, by Disease Type
  - 7.3.5.3.2 Market size and forecast, by Route of administration
  - 7.3.5.3.3 Market size and forecast, by End user
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Market size and forecast, by Disease Type
  - 7.3.5.4.2 Market size and forecast, by Route of administration
  - 7.3.5.4.3 Market size and forecast, by End user
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Market size and forecast, by Disease Type
  - 7.3.5.5.2 Market size and forecast, by Route of administration
  - 7.3.5.5.3 Market size and forecast, by End user
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Market size and forecast, by Disease Type
  - 7.3.5.6.2 Market size and forecast, by Route of administration
  - 7.3.5.6.3 Market size and forecast, by End user
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Disease Type
- 7.4.3 Asia-Pacific Market size and forecast, by Route of administration
- 7.4.4 Asia-Pacific Market size and forecast, by End user
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 China
  - 7.4.5.1.1 Market size and forecast, by Disease Type
  - 7.4.5.1.2 Market size and forecast, by Route of administration
  - 7.4.5.1.3 Market size and forecast, by End user
  - 7.4.5.2 Japan
  - 7.4.5.2.1 Market size and forecast, by Disease Type
  - 7.4.5.2.2 Market size and forecast, by Route of administration
  - 7.4.5.2.3 Market size and forecast, by End user
  - 7.4.5.3 India
  - 7.4.5.3.1 Market size and forecast, by Disease Type
  - 7.4.5.3.2 Market size and forecast, by Route of administration
  - 7.4.5.3.3 Market size and forecast, by End user
  - 7.4.5.4 Australia
  - 7.4.5.4.1 Market size and forecast, by Disease Type
  - 7.4.5.4.2 Market size and forecast, by Route of administration
  - 7.4.5.4.3 Market size and forecast, by End user
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Market size and forecast, by Disease Type
  - 7.4.5.5.2 Market size and forecast, by Route of administration
  - 7.4.5.5.3 Market size and forecast, by End user
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Market size and forecast, by Disease Type
  - 7.4.5.6.2 Market size and forecast, by Route of administration
  - 7.4.5.6.3 Market size and forecast, by End user
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Disease Type
- 7.5.3 LAMEA Market size and forecast, by Route of administration
- 7.5.4 LAMEA Market size and forecast, by End user
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Market size and forecast, by Disease Type
  - 7.5.5.1.2 Market size and forecast, by Route of administration
  - 7.5.5.1.3 Market size and forecast, by End user
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Market size and forecast, by Disease Type
  - 7.5.5.2.2 Market size and forecast, by Route of administration
  - 7.5.5.2.3 Market size and forecast, by End user
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Market size and forecast, by Disease Type
  - 7.5.5.3.2 Market size and forecast, by Route of administration
  - 7.5.5.3.3 Market size and forecast, by End user
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Market size and forecast, by Disease Type
  - 7.5.5.4.2 Market size and forecast, by Route of administration
  - 7.5.5.4.3 Market size and forecast, by End user

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 Alnylam Pharmaceuticals
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 BioNTech AG
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Curevac AG
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Etherna Immunotherapies
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Ethris GMBH
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 IN-CELL-ART
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Moderna Therapeutics
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Sangamo Therapeutics, Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Sanofi AG
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 SCM Life Sciences (Argos Therapeutics, Inc. )
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
9.11 Sarepta Therapeutics
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
9.12 Arcturus Therapeutics
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
9.13 Ionis Pharmaceuticals, Inc
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
9.14 Nutcracker
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
9.15 Tiba Biotech
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments